The European Union’s (EU’s) scientific advisory organization dealing with new human pharmaceuticals approval. Its recommendations (e.g., to either approve or not approve a new product) are usually adopted by the European Medicines Evaluation Agency (EMEA), to which the CPMP reports.
Within 60 days of a CPMP “approval for recommendation” being adopted by the EMEA, each of the EU’s member countries must advise the EMEA of its progress toward a regulatory decision on that pharmaceutical’s submission for approvals.